Skip to content

Application value of combined novel biomarkers (urinary NGAL, KIM-1, IGFBP7 and TIMP-2) in early diagnosis and staging system of acute kidney injury (AKI) in patients with cirrhosis

Application value of combined novel biomarkers (urinary NGAL, KIM-1, IGFBP7 and TIMP-2) in early diagnosis and staging system of acute kidney injury (AKI) in patients with cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065456
Enrollment
Unknown
Registered
2022-11-04
Start date
2022-10-31
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis and complications

Interventions

Gold Standard:AKI was diagnosed as a >= 26.5 umol/L increase in serum creatinine within 48 hours or a >= 50% increase in serum creatinine level from baseline within 7 days. In AKI stage 1, serum creat
In AKI stage
Index test:Urinary tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), Insulin-like growth factor-binding protein 7 (IGFBP7), Urinary neutrophil gelatinase-associated lipocalin (NGAL), Urinary ki

Sponsors

Department of Infection, Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients hospitalized in Changhai Hospital for decompensation of liver cirrhosis; 2. Ability to understand and sign informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Patients with severe advanced liver cancer or extrahepatic malignancy; 2. Patients with chronic kidney disease and structural kidney injury; 3. Patients with severe cardiopulmonary dysfunction; 4. Patients whose condition cannot be monitored during hospitalization due to liver transplantation, death from non-AKI, or other reasons; 5. Pregnant or lactating women; 6. The investigators believe there may be patients with poor compliance.

Design outcomes

Primary

MeasureTime frame
Novel urinary biomarkers (NGAL, KIM-1, IGFBP7 and TIMP-2);

Countries

China

Contacts

Public ContactLi Chengzhong

Changhai Hospital

Leo_lee66@126.com+86 13601681659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026